logo
Share SHARE
FONT-SIZE Plus   Neg

Threshold Pharma's TH-302 Receives EC's Orphan Drug Designation

Threshold Pharmaceuticals, Inc. (THLD) Friday said the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma.

Soft tissue sarcoma is an aggressive form of cancer and there is a significant unmet medical need for the condition. TH-302 was designed to selectively target hypoxic regions within tumors, which are believed not effectively treated with current therapy.

Threshold is currently conducting a pivotal Phase 3 study in soft tissue sarcoma, comparing TH-302 in combination with doxorubicin against single agent doxorubicin.

"The Orphan Drug Designation was granted as early studies of TH-302 have shown that it might be of significant benefit for patients with soft tissue sarcoma when combined with doxorubicin," said Barry Selick, Ph.D., CEO of Threshold.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of social network company Twitter Inc. (TWTR), jumped over 5 percent on Wednesday, after one of its cofounders Ev Williams dropped a hint during a television interview about the company's sale. Ev Williams, a Twitter cofounder and board member, was asked by Bloomberg TV about the company's... Mazda Motor Corp. (MZDAF.PK) is recalling over 190,000 CX-7 sport utility vehicles to fix a issue that could lead to loss of steering control. The recall involves CX-7 models from 2007 through 2012 manufactured between February 14, 2006 to May 9, 2012. The company said there have been no reports of... Over 68 million email address and passwords of Dropbox users were stolen by hackers, according to a report from Motherboard. Although, the account details were stolen during a previously disclosed breach that took place in 2012, the magnitude of the attack has come to light only now. Following...
comments powered by Disqus
Follow RTT